ArticleJournal of thoracic disease2026
First-line third-generation EGFR-TKIs for advanced EGFR-mutated non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost-effectiveness of first-line aumolertinib versus osimertinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer in China.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head‑to‑head comparisons among first‑line third‑generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for EGFR‑mutated unresectable non-small cell lung cancer (NSCLC) are nearly absent. This network meta‑analysis compares the efficacy and safety of all available agents and provide evidence-based references for clinical decision-making. Methods: We searched PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to April 2026. Eligible studies were randomized controlled trials (RCTs) enrolling patients with advanced EGFR-mutated NSCLC receiving first-line third-generation EGFR-TKIs compared with first-generation EGFR-TKIs. Two reviewers independently extracted data and assessed risk of bias using the Cochrane RoB 2 tool. The primary efficacy outcome was progression-free survival (PFS). We performed a network meta-analysis (NMA) using a fixed-effect model and ranked treatments using surface under the cumulative ranking curve (SUCRA). The protocol was registered with PROSPERO (CRD42022349097). Results: Eleven RCTs comprising 4,663 patients were analyzed. All investigated third-generation agents (aumolertinib, osimertinib, furmonertinib, befotertinib, limertinib, rilertinib, lazertinib, and rezivertinib) demonstrated superior PFS compared to first-generation TKIs. However, no statistically significant PFS differences were observed among the third-generation agents. Similarly, no significant differences were found between third- and first-generation TKIs regarding objective response rate (ORR) or ≥ G3 treatment-emergent adverse events (TEAEs). Subgroup analyses revealed no significant PFS benefit for befotertinib over first-generation TKIs in the L858R subgroup, nor for befotertinib or furmonertinib in elderly patients. Conclusions: Most third-generation TKIs offer superior PFS compared to first-generation agents, with comparable efficacy observed across the third-generation agents. Safety profiles, specifically regarding high-grade adverse events, appear similar between third- and first-generation TKIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.